Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

Peer Review reports

Original Submission
27 Sep 2019	Submitted	Original manuscript
14 Dec 2019	Reviewed	Reviewer Report - Sachio Fushida
28 May 2020	Author responded	Author comments - Kenro Hirata
3 Jun 2020	Author responded	Author comments - Kenro Hirata
Resubmission - Version 2
28 May 2020	Submitted	Manuscript version 2
Publishing
6 Jun 2020	Editorially accepted
12 Jun 2020	Article published	10.1186/s12885-020-07047-1

Back to article page